August 2016, Vol. 5, No. 6
Presenting Emerging Data and Calling for Molecular Tumor Board Case StudiesLetter to Our Readers
On behalf of all of us at Personalized Medicine in Oncology (PMO), I hope you are enjoying the summer and finding time for the recreation necessary to return to the care of your patients with a renewed spirit. After the busy ASCO season, we have taken advantage of this time to review data from this important meeting and are pleased to offer the most critical information in this issue. You’ll find a host of the best reports from ASCO all related to personalized medicine, from the latest in immunotherapies and matching therapy to molecular alterations. We hope this compilation is of value to you and your practice.
Also in this issue, we are delighted to feature an article by PMO Editorial Board member Darren Sigal, MD, and his colleague David Hermel, MD. The authors take a critical look at emerging data regarding anti–PD-1 agents as biomarkers.
Many oncology centers host molecular tumor boards during which multidisciplinary participants discuss patients with all types of cancer whose tumors have been analyzed with advanced genomic diagnostic tests. If you participate in such a board, we want to hear from you with your case study submissions for our Molecular Tumor Board department. Submissions should include case presentation, actionable biomarker identification, therapeutic course, and outcomes. Author guidelines can be found at www.personalizedmedonc.com/author-guidelines.
Enjoy what remains of summer, and we hope you will consider submitting a case study. Thank you for your loyal readership.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
Interim results from a phase 1b study indicate that the monoclonal antibody isatuximab in combination with lenalidomide and dexamethasone results in responses in more than 50% of patients with relapsed/refractory multiple myeloma (MM), including those refractory to immunomodulatory therapy. Based on the positive findings from this trial, a global phase [ Read More ]
Venetoclax, an investigational oral selective small molecule Bcl-2 inhibitor, added to bortezomib and dexamethasone resulted in impressive response rates in a phase 1b trial of patients with heavily pretreated relapsed/refractory (RR) multiple myeloma (MM). In the trial, the objective response rate (ORR) was higher among patients whose myeloma cells produced [ Read More ]